UroGen Pharma Ltd. (URGN)
NASDAQ$11.07
Market Cap
$510.27M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
895 of 924
Rank in Industry
511 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
URGN Insider Trading Activity
URGN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $400,032 | 6 | 100 |
Related Transactions
| Smith Jason Drew | General Counsel | 0 | $0 | 2 | $102,097 | $-102,097 |
| Schoenberg Mark | Chief Medical Officer | 0 | $0 | 4 | $297,935 | $-297,935 |
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma …
Insider Activity of UroGen Pharma Ltd.
Over the last 12 months, insiders at UroGen Pharma Ltd. have bought $0 and sold $400,032 worth of UroGen Pharma Ltd. stock.
On average, over the past 5 years, insiders at UroGen Pharma Ltd. have bought $264,948 and sold $340,114 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 160 shares for transaction amount of $2,096 was made by Schoenberg Mark (Chief Medical Officer) on 2021‑11‑18.
List of Insider Buy and Sell Transactions, UroGen Pharma Ltd.
| 2025-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 4,551 0.0106% | $11.14 | $50,698 | -3.63% | |
| 2025-01-31 | Sale | Smith Jason Drew | General Counsel | 7,379 0.0172% | $11.14 | $82,202 | -3.63% | |
| 2024-09-09 | Sale | Schoenberg Mark | Chief Medical Officer | 859 0.002% | $13.08 | $11,236 | -14.27% | |
| 2024-09-09 | Sale | Smith Jason Drew | General Counsel | 1,521 0.0035% | $13.08 | $19,895 | -14.27% | |
| 2024-06-10 | Sale | Schoenberg Mark | Chief Medical Officer | 5,153 0.0146% | $13.08 | $67,401 | -2.58% | |
| 2024-03-18 | Sale | Schoenberg Mark | Chief Medical Officer | 12,000 0.0341% | $14.05 | $168,600 | -10.55% | |
| 2024-02-01 | Sale | Schoenberg Mark | Chief Medical Officer | 3,789 0.0123% | $15.78 | $59,790 | -14.81% | |
| 2024-02-01 | Sale | Smith Jason Drew | General Counsel | 4,993 0.0162% | $15.78 | $78,790 | -14.81% | |
| 2024-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 3,789 0.0122% | $15.74 | $59,639 | -13.69% | |
| 2024-01-31 | Sale | Smith Jason Drew | General Counsel | 4,993 0.0161% | $15.74 | $78,590 | -13.69% | |
| 2023-08-31 | Sale | Smith Jason Drew | General Counsel | 3,800 0.0129% | $18.01 | $68,438 | -16.42% | |
| 2023-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 1,900 0.0079% | $10.12 | $19,228 | +14.73% | |
| 2023-01-31 | Sale | Smith Jason Drew | General Counsel | 1,636 0.0068% | $10.12 | $16,556 | +14.73% | |
| 2022-10-31 | Sale | Schoenberg Mark | Chief Medical Officer | 258 0.0011% | $11.85 | $3,057 | -12.32% | |
| 2022-08-31 | Sale | Smith Jason Drew | General Counsel | 3,606 0.0153% | $7.21 | $25,999 | +29.66% | |
| 2022-07-31 | Sale | Schoenberg Mark | Chief Medical Officer | 259 0.0011% | $7.81 | $2,023 | +24.87% | |
| 2022-04-30 | Sale | Schoenberg Mark | Chief Medical Officer | 254 0.001% | $6.62 | $1,681 | +27.18% | |
| 2022-01-31 | Sale | Barrett Elizabeth A. | Chief Executive Officer | 8,195 0.0356% | $7.58 | $62,118 | +5.96% | |
| 2022-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 1,374 0.006% | $7.58 | $10,415 | +5.96% | |
| 2022-01-31 | Sale | Smith Jason Drew | General Counsel | 414 0.0018% | $7.58 | $3,138 | +5.96% |
Total: 69
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Schoenberg Mark | Chief Medical Officer | 145666 0.316% | $1.61M | 3 | 29 | <0.0001% |
| Smith Jason Drew | General Counsel | 26468 0.0574% | $293,000.76 | 1 | 9 | <0.0001% |
| Barrett Elizabeth A. | Chief Executive Officer | 300985 0.653% | $3.33M | 4 | 2 | <0.0001% |
| Henderson Molly | Chief Financial Officer | 5248 0.0114% | $58,095.36 | 1 | 2 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$587,109,125 | 90 | 3.17% | $527.16M | |
$24,384,691 | 42 | -30.27% | $455.92M | |
$678,065,999 | 37 | -13.32% | $603.22M | |
$16,271,606 | 27 | 24.11% | $601.57M | |
$54,828,550 | 26 | -13.88% | $493.09M |
URGN Institutional Investors: Active Positions
| Increased Positions | 71 | +48.63% | 10M | +28.52% |
| Decreased Positions | 59 | -40.41% | 8M | -21.35% |
| New Positions | 30 | New | 7M | New |
| Sold Out Positions | 20 | Sold Out | 642,229 | Sold Out |
| Total Postitions | 158 | +8.22% | 39M | +7.17% |
URGN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rtw Investments, Lp | $36,277.00 | 9.13% | 3.83M | +47,447 | +1.25% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $27,700.00 | 6.97% | 2.93M | -807,655 | -21.62% | 2024-12-31 |
| Blackrock, Inc. | $23,340.00 | 5.87% | 2.47M | -30,732 | -1.23% | 2024-12-31 |
| Menora Mivtachim Holdings Ltd. | $21,787.00 | 5.48% | 2.3M | 0 | 0% | 2024-12-31 |
| Cowen And Company, Llc | $16,996.00 | 4.28% | 1.8M | -302,893 | -14.43% | 2024-09-30 |
| Toronto Dominion Bank | $16,547.00 | 4.17% | 1.75M | +2M | New | 2024-12-31 |
| Vestal Point Capital, Lp | $15,420.00 | 3.88% | 1.63M | +1M | +307.5% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $14,344.00 | 3.61% | 1.52M | +2M | New | 2024-12-31 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $13,028.00 | 3.28% | 1.38M | +36,084 | +2.69% | 2024-12-31 |
| Nantahala Capital Management, Llc | $12,976.00 | 3.27% | 1.37M | +1M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.